| Title : Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas - van den Bent_1998_Eur.J.Cancer_34_1570 |
| Author(s) : van den Bent MJ , Schellens JH , Vecht CJ , Sillevis Smit PA , Loosveld OJ , Ma J , Tijssen CC , Jansen RL , Kros JM , Verweij J |
| Ref : Eur J Cancer , 34 :1570 , 1998 |
|
Abstract :
27 patients with recurrent high grade glioma following surgery and radiation therapy were treated with 100 mg/m2 cisplatin and 6 g/m2 ifosfamide per cycle, administered on days 1-3 in 4 week cycles, for a maximum of six cycles. Toxicity was assessed after every cycle. Response was assessed following every second cycle, and a 50% decrease of the largest cross-sectional tumour area on contrast enhanced magnetic resonance imaging or computed tomography scan was considered a partial response (PR). A total of 95 cycles was administered; 26 patients were evaluable for response. In 5 patients (19%), a PR was obtained (median time to progression (TTP): 34 weeks). Stable disease was observed in 6 patients (23%, median TTP: 22 weeks). The most frequent toxicity was haematological: 37% of cycles were complicated by a grade 3 or 4 leucopenia. 1 patients died, probably as a consequence of increased cerebral oedema induced by the cisplatin hydration schedule. Determination of the cisplatin concentration in this patient showed a 10-fold increase in the tumour concentration as compared with that in normal brain tissue, demonstrating the absence of a blood-brain barrier in the tumour. In conclusion, generally this schedule was well tolerated, but it is of moderate activity for recurrent glioma. |
| PubMedSearch : van den Bent_1998_Eur.J.Cancer_34_1570 |
| PubMedID: 9893630 |
van den Bent MJ, Schellens JH, Vecht CJ, Sillevis Smit PA, Loosveld OJ, Ma J, Tijssen CC, Jansen RL, Kros JM, Verweij J (1998)
Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas
Eur J Cancer
34 :1570
van den Bent MJ, Schellens JH, Vecht CJ, Sillevis Smit PA, Loosveld OJ, Ma J, Tijssen CC, Jansen RL, Kros JM, Verweij J (1998)
Eur J Cancer
34 :1570